AbbVie would gain an experimental eczema drug by buying biotech: report

AbbVie is reportedly seeking to acquire a biotech company developing a promising atopic dermatitis drug for $10.9 billion in cash. The deal would be a meaningful M&A move in healthcare and could strengthen AbbVie’s pipeline in immunology. The report is likely to be positive for the target and mildly supportive for AbbVie if completed, though it remains unconfirmed.

Analysis

AbbVie is reportedly seeking to acquire a biotech company developing a promising atopic dermatitis drug for $10.9 billion in cash. The deal would be a meaningful M&A move in healthcare and could strengthen AbbVie’s pipeline in immunology. The report is likely to be positive for the target and mildly supportive for AbbVie if completed, though it remains unconfirmed.